LAVA Therapeutics NV (LVTX) — Cash Flow-to-Debt Ratio
LAVA Therapeutics NV (LVTX) has a Cash Flow-to-Debt Ratio of -0.12x as of September 2025, meaning its operating cash flow of $-4.87 Million could theoretically repay 0% of its total liabilities ($39.23 Million) in one year. See how financially flexible is LAVA Therapeutics NV to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
LAVA Therapeutics NV Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for LAVA Therapeutics NV across 6 annual periods. For the full cash flow conversion analysis, see LAVA Therapeutics NV operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for LAVA Therapeutics NV (2019–2024)
Year-by-year debt coverage analysis for LAVA Therapeutics NV. Check LVTX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.37x | $-19.54 Million | $53.09 Million | ▲ +53.8% |
| 2023 | -0.80x | $-40.28 Million | $50.53 Million | ▼ -1231.5% |
| 2022 | 0.07x | $4.04 Million | $57.38 Million | ▲ +105.1% |
| 2021 | -1.37x | $-28.65 Million | $20.88 Million | ▼ -89.6% |
| 2020 | -0.72x | $-9.31 Million | $12.87 Million | ▲ +75.2% |
| 2019 | -2.92x | $-8.62 Million | $2.95 Million | — |